IRCT20080921001264N11 IRCT 2020-06-29 Gorgan University of Medical Sciences Role of somatostatin in the incidence of post – ERCP pancreatitis Assessment the role of somatostatin and indomethacin versus only indomethacin in the incidence of post – ERCP pancreatitis 2018-03-21 anticipated 360 Complete https://irct.ir/trial/49015 interventional Randomization: Randomized, Blinding: Triple blinded, Placebo: Used, Assignment: Parallel, Purpose: Prevention, Randomization description: In this way, using the Block Balanced Randomization method with four blocks and preparing a list of blocks and assigning numbers to them, a list of treatment allocations is prepared and patients are assigned to one of the somatostatin and indomethacin groups or indomethacin group according to the list, Blinding description: Due to the use of numbers to randomly assign patients to treatment groups and the use of quadruple blocks, all patients are coded. Patients in the intervention group and patients in the control and subspecialty group of gastroenterologists performing ERCP, the laboratory assessing the level of amylase, and the statistical consultant analyzing the data will be unaware of which group the patient belongs to. Evaluation and increase of accuracy and objectivity of clinical results were performed. 4 Pancreatitis. Intervention 1: Intervention group: somatostatin plus indometacin. Somatostatin 250 μg bolus for 1-2 minutes pre-ERCP Long-term infusion of somatostatin 500μg, started during ERCP and lasted for two hours ‎Indomethacin suppository 100mg pre-ERCP and 100mg post-ERCP. Intervention 2: Control group: Indomethacin alone. For control group, normal saline and indomethacine suppository (100 mg) were administrated before and after ERCP.‎. Yes - There is a plan to make this available What will be shared: All potential data can be shared after people have not been identified When: from December 2020 To whom: all Conditions: - Where to obtain: To the PI of the study How to obtain: research deputy Comments: